 Down-regulation of PP4c increases cell survival, migration and attenuates basal apoptosis in breast cancer cells.
Abstract

Background
The control of breast cell survival is of critical importance for preventing breast cancer initiation and progression. The activity of many proteins which regulate cell survival is controlled by reversible phosphorylation, so that the relevant kinases and phosphatases play crucial roles in determining cell fate. Several protein kinases act as oncoproteins in breast cancer and changes in their activities contribute to the process of transformation. Through counteracting the activity of oncogenic kinases, the protein phosphatases are also likely to be important players in breast cancer development, but this class of molecules is relatively poorly understood. Here we have investigated the role of the serine/ threonine protein phosphatase 4 in the control of cell survival of breast cancer cells.
Methods
The breast cancer cell lines, MCF7 and MDA-MB-231, were transfected with expression vectors encoding the catalytic subunit of protein phosphatase 4 (PP4c) or with PP4c siRNAs. Culture viability, apoptosis, cell migration and cell cycle were assessed. The involvement of phosphoprotein enriched in astrocytes 15 kD (PEA15) in PP4c action was investigated by immunoblotting approaches and by siRNAmediated silencing of PEA15.
Results
In this study we showed that PP4c over-expression inhibited cell proliferation, enhanced spontaneous apoptosis and decreased the migratory and colony forming abilities of breast cancer cells. Moreover, PP4c down-regulation produced complementary effects. PP4c is demonstrated to regulate the phosphorylation of
Introduction
Breast cancer is a highly complex and heterogeneous disease, and can be classified into different molecular subtypes according to the expression status of oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptors (HERs), HER2/Neu and HER1/EGFR [1, 2] . Phosphorylation of these receptors on tyrosine (Tyr) residues constitutes a major regulatory mechanism of their activities. Aberrant activation of these receptors dysregulates multiple signalling cascades and plays a vital role in the initiation, development and progression of breast cancer, highlighting the importance of protein phosphorylation in the context of breast oncogenesis [3] . While the protein tyrosine kinase (PTK) families comprising the HERs and the non-receptor Src-family kinases (SFKs) have been directly implicated in the development and progression of breast cancer [3] , their downstream signalling is mainly mediated via the activation of effector pathways that involve serine/threonine (Ser/Thr) kinases, including MAP kinase (MAPK), the phosphoinositide-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and the JAK/STAT signalling pathways [4] . The role of Ser/Thr kinases in breast cancer as crucial effectors in oncogenic PTK signalling has been well studied and multiple compounds that target their activity are being evaluated in clinical trials [5] .
In contrast, the role of protein phosphatases, the enzymes that reverse the action of protein kinases, is relatively under-studied. This is despite the tumour suppressor function of protein phosphatase 2A (PP2A), a major serine/threonine phosphatase, having been clearly demonstrated in breast, gastric and ovarian cancer cells [6] .
Notably, the Ser/Thr phosphatase family contains a number of other subfamilies (i.e. PP1, PP4, PP5, PP6 and PP7), the tumour suppressive functions of which remain to be explored in detail in breast cells [7] . Nevertheless, evidence is emerging from other cell types to indicate a crucial role for the PP4 subfamily in the control of cell survival, in particular [7] . PP4 (Protein phosphatase 4; PPP4; PPX) exists as a holoenzyme composed of a highly conserved catalytic subunit (PP4c) which interacts with different structural and regulatory subunits which control its activity, as well as its subcellular localisation [7] . A vast array of regulatory subunits have been described, including alpha 4/ immunoglobulin (CD79A) binding protein 1 (4/ IGBP1) which is the only subunit shared with PP2A [8] [9] [10] [11] [12] [13] .
Like PP2A, PP4 complexes are involved in multiple fundamental cellular processes, including nucleation, organelle assembly, regulation of microtubule growth, growth and maturation of the centrosome during cell division, cell migration, as well as spliceosomal assembly via interaction with the SMN complex [14, 9] . At the molecular level, PP4 controls haematopoietic progenitor kinase 1 (HPK1), NFκB and histone deacetylase activities [15] [16] [17] and regulates JNK and the target of rapamycin (TOR) signalling pathways [18] . PP4 also regulates the dephosphorylation of H2AX, the replication protein A (RPA) [19, 20] and KRAB-domain-associated protein 1 (KAP-1) implicating it in regulation of the DNA damage response [21] .
Accumulating evidence has demonstrated that the catalytic subunit of PP4 (PP4c) plays important and complex roles in apoptosis and cell proliferation and consequently, in cancer. Over-expression of PP4c increases cell death and decreases cell proliferation in mouse thymoma cells [22] , in the human embryonic kidney cell line HEK 293T [22] , and in both leukemic T-cells and untransformed human peripheral T-cells [23] . In the latter cells, down-regulation of PP4c causes an increase in the rate of cell proliferation and confers resistance to a number of apoptotic stimuli [23] . On the other hand, a reduction in endogenous PP4c increases the basal apoptotic rate of A549 and HeLa cells [24] . Such cell-specific effects of PP4c on cell survival could be related to the differential expression of the various regulatory subunits, resulting in the formation of PP4 complexes with distinct subcellular locations and molecular targets. Overall, these observations suggest that PP4c dysfunction may be important in the development and progression of cancer.
The additional observation that PP4c expression is elevated in breast cancer [25, 26] , further highlights the need for further studies to characterise its role in breast cells.
Proteomic analysis has shown that changes in PP4c expression in human embryonic kidney 293T cells affects the phosphorylation status of many proteins involved in apoptosis and cell proliferation, including the critical apoptosis regulator, phosphoprotein enriched in astrocytes 15 kD (PEA15) [27] . Further analysis has confirmed the interaction between PP4c and PEA15 and demonstrates that PP4c -induced apoptosis in normal lymphocytes and T-leukemic cells is partly mediated through the direct or indirect dephosphorylation of PEA15 [23] . PEA15 is a member of the death effector domain (DED) protein family known to regulate cell proliferation, autophagy, and apoptosis [28, 29] . It is implicated in the dysregulation of many signalling pathways involved in cancer progression and tumorigenesis and it has been described to act as both a tumour suppressor and a tumour promoter, dependent on its phosphorylation status [30] [31] [32] . The PEA15 gene is amplified in breast cancer, as well as in other cancers [33] , and the unphosphorylated form of PEA15 is more potent than the phosphorylated form in suppressing tumorigenicity in breast cancer [34] . While several kinases have been reported to be involved in the phosphorylation of PEA15 including Akt, Ca2+/calmodulin-dependent protein kinase (CaMKII) and AMP-activated protein kinase (AMPK) [35, 36] , the dephosphorylation of PEA15 is much less understood.
In this study, we have investigated the role of PP4c in the control of survival of hormone-sensitive and triple-negative breast cancer cells. Firstly, we have investigated the hypothesis that PP4c regulates the survival and proliferation of breast cancer cells. Secondly, we have explored the interaction between PP4c and PEA15 and have specifically addressed the involvement of PEA15 in mediating the functional responses of breast cancer cells to PP4c. Together, these studies reveal the importance of PP4c expression levels in the control of survival of breast cancer cells and provide support for a tumour suppressor role for PP4c. Our findings also indicate that the critical role played by PP4c in maintaining the delicate balance between cell survival and cell death in breast cancer cells is mediated, at least partly, through the dephosphorylation of PEA15.
Materials and methods
1. Cell culture
The breast cancer cell lines MCF7 [37] and MDA-MB-231 [38] were generated from secondary stocks of cells which had been frozen down within two weeks of receipt from ATCC-LGC Promochem (Teddington, Middlesex, UK). Cells were cultured in R-10 medium (RPMI-1640; Sigma Aldrich Company Ltd) supplemented with 2 mM Lglutamine, 1 mM sodium pyruvate, 10 mM HEPES, 10% fetal bovine serum and 50 µg/ml gentamicin at 37 °C in a humidified incubator with 5% CO 2 . Cell lines were replaced with freshly thawed stocks every 6 -8 weeks. All experiments were carried out using cells in logarithmic growth phase.
Plasmid DNA transfection
Plasmids were pcDNA3.1-PP4c [23, 27] , and empty pcDNA3.1 vector as control. 
3. RNA interference
MCF7 and MDA-MB-231 breast cancer cells were transfected with siRNAs to PP4c, using RNAiFect reagent (Qiagen, Crawley, UK) according to a standard protocol [39] .
Three different PP4c specific siRNAs were employed, termed PP4s1 (targets exon 7;
product code n105835), PP4s2 (targets exon 4; product code n105834) and PP4s8
(targets exon 6, product code SI02658698); PP4s1 and PP4s2 were purchased from Life Technologies Ltd (Paisley, UK), whereas PP4s8 was purchased from Qiagen were suspended in 200 µl phosphate buffered saline (PBS), and fixed in 1 ml icecold 70% ethanol/30% PBS. Cells were incubated at -20 °C for at least three hours.
Cells were then re-suspended in 200 µl of Muse™ Cell Cycle Reagent and incubated for 30 minutes in the dark before data was acquired using the Muse Cell analyser.
6. Western blot analysis
Cells (10 6 ) were washed twice in PBS and lysed in 50 μl lysis buffer (50 mM TrisHCl, pH 7.5; 150 mM NaCl, 1% Nonidet P40, 1 mM EDTA, 1 μM Pepstatin, 10 μg/ml Leupeptin, 1 mM PM Phenylmethanesulfonyl fluoride (PMSF)) on ice for 30 min. (Fig. 1B and S1A ). Cells over-expressing PP4c also showed a 15-20% increase in apoptotic cells ( Fig. 1C and S1B ). In order to determine whether the growth suppression produced by PP4c was due to apoptosis, to cell cycle arrest, or to both, a cell cycle analysis was performed using propidium iodide staining and flow cytometry. The results revealed a significant increase in the proportion of cells in the sub-G0 phase in PP4c over-expressing cultures, suggesting an increase in the apoptosis rate, and a consistently lower percentage of cells in G1 and S phases (Fig.   1D ). In the longer term, these various effects resulted in a significant decrease in the clonogenic activity of MCF7 cells (Fig. 1E ).
To confirm these findings, the triple-negative breast cancer (TNBC) cell line, MDA-MB-231, was transfected with the plasmid encoding PP4c. This also produced an approximate doubling of cellular PP4c protein levels ( Fig. 2A) and caused a significant reduction in total and viable cell number ( Fig. 2B and S2A ). This was also associated with a doubling of basal apoptosis ( Fig. 2C and S2B ). Cell cycle analysis confirmed an increase in the proportion of cells in the sub-G0 fraction after transfection with pcDNA3.1-PP4c, whereas the proportions of cells in G1, S and G2/M phases were decreased (Fig. 2D) . Over-expression of PP4c in MDA-MB-231 also caused a significant reduction in the clonogenic activity of these cells (Fig. 2E) .
Thus, PP4c causes growth arrest, induces apoptosis and decreases long term In MCF7 cells, the two PP4c-targeted siRNAs each reduced PP4c protein levels by 70 -80% (Fig. 3A) . Both siRNAs increased the numbers of total and viable cells ( Fig.   3B and S3A) and decreased the level of basal apoptosis ( Fig. 3C and S3B ). Cell cycle analysis revealed that PP4c silencing decreased the proportion of cells in sub-G0 and increased the proportions of cells in S and G2/M phases (Fig. 3D) . The clonogenic activity of MCF7 cells was also increased in the cells transfected with PP4c specific siRNAs (Fig. 3E ).
siRNA-mediated silencing of PP4c expression in MDA-MB-231 produced an 80 -85% decrease in endogenous PP4c protein levels (Fig. 4A) . As in MCF7 cells, this was associated with an increase in the number of total and viable cells ( Fig. 4B and   S4A ) and a decrease in spontaneous apoptosis ( Fig. 4C and S4B ). Cell cycle analysis confirmed that PP4c silencing produced a substantial reduction in the proportion of cells in the sub-G0 fraction (Fig. 4D) . The proportion of cells in G1 was also consistently lower compared to the negative control siRNA, whereas the proportion of cells in S and G2/M phases was consistently higher, suggesting that PP4c down-regulation may accelerate G1 progression (Fig. 4D ). PP4c silencing also significantly increased the long term survival of MDA-MB-231, as shown by an increase in the number of colonies formed (Fig. 4E ).
The effect of PP4c silencing on cell migration was also assessed using an in-vitro ability by 30% at 18 h and by 20% at 36 and 54 h (Fig. 5B) . Overall, the data indicate that PP4c down-regulation enhances breast cancer cell proliferation and migration, with implications for breast cancer progression and metastasis.
3. 3. PP4c down-regulation leads to an increase in the PEA15 Ser116 phosphorylation PEA15 is one of the proteins reported to be regulated, directly or indirectly, through dephosphorylation by PP4c [30, 35] . Previous studies have shown that overexpression of PP4c correlates with dephosphorylation of PEA15 on Ser116, while
PP4c silencing results in an increase in the level of phosphorylated Ser116 [23, 27] . The control of apoptosis and cell proliferation by PP4c in leukemic and primary human T-cells was demonstrated to be mediated at least partly through the dephosphylation of PEA15 on Ser116 [23, 27] . Further experiments were carried out in order to investigate whether PEA15 plays a major role in mediating the proapoptotic and growth inhibitory effects of PP4c in breast cancer cells. Two PEA15-specific siRNAs were used to down-regulate PEA15 before studying the effects of modulation of PP4c expression on cell viability. Down-regulation of PEA15 in MCF7
cells was assessed at 48 h post-transfection which showed that both PEA15 siRNAs were effective in causing a decrease in PEA15 protein levels by 60 -75% (Fig. 7A ).
In agreement with a previous study [36] , down-regulation of PEA15 resulted in significant decreases in the number of viable cells (Fig. 7B ) and cell viability (Fig.   7C ), and a significant increase in basal apoptosis (Fig. 7D) . Consistent with these observations, silencing of PEA15 gene expression in MDA-MB-231 cells also resulted in a decrease in PEA15 protein levels (Fig. 8A ) and this was accompanied by reductions in the viable cell number (Fig. 8B ) and cell viability (Fig. 8C) , and an increase in basal apoptosis (Fig. 8D) , confirming an oncogenic role for PEA15 over- caused the expected reduction in viable cell number (Fig. 9A ) and the expected increase in basal apoptosis (Fig. 9B ). In contrast, over-expression of PP4c in cells which had been previously transfected with PEA15 siRNA had no effects on the viable cell number and apoptosis level (Fig. 9A, B) . These findings were confirmed in the TNBC MDA-MB-231 cells. Over-expression of PP4c in (-)siRNA transfected cells decreased the number of viable cells by more than 40% and enhanced the level of basal apoptosis but had no effect on the number of viable cells and the level of apoptosis (Fig. 9C,D) .
Discussion
Reversible protein phosphorylation, controlled by the opposing action of protein kinases and phosphatases, regulates many cellular processes. Disturbance to the well balanced function of kinases and phosphatases contributes to the development and progression of various cancers including breast cancer [5] . Many kinases are now characterised to be oncogenic and changes in their activities have been linked to the pathogenesis and progression of breast cancer. However, the roles played by the phosphatases are much less clear and less well studied, although logically, they must be important through their ability to counteract the activities of the kinases [5] .
Indeed, phosphatases such as PP2A [41, 42] , phosphatase and tensin homologue [7, 16] . The enzyme is involved in the regulation of microtubule growth and organization at the centrosomes [9] , centrosome maturation in mitosis and meiosis and DNA damage response [8, 44] . Recent evidence suggested that PP4c controls neural progenitor cell proliferation and differentiation in the mouse neocortex by regulating the phosphorylation status of Nuclear distribution protein nudE-like1 (Ndel1) [34] . PP4c interacts with and down-regulates insulin receptor substrate 4 (IRS4) following tumour necrosis factor-alpha (TNF-α) stimulation leading to the inhibition of the anti-apoptotic function of IRS4 [45] . Such evidence is entirely consistent with the findings form the present studies and suggest potential downstream mechanisms underlying regulation of cell survival by PP4c in a cell context-dependent manner.
On the other hand, the exact role of PP4c in relation to cancer is not clear, with some studies suggesting a tumour suppressor role, while others support an oncogenic role. For example, PP4c levels are increased in human breast and lung tumours, and inhibition of PP4c expression increased the sensitivity of breast and lung cancer cells to cisplatin treatment, suggestive of an oncogenic function [25] .
PP4c is also over-expressed in pancreatic ductal adenocarcinoma (PDAC) and is associated with a poor prognosis [26] . Also PP4c has been reported to be expressed suggesting that PP4R1-PP4c complex serves as a negative regulator of IKK activity [16] . It is therefore important to elucidate the functional status of the catalytic subunits in breast cancer and further investigate the precise roles of other individual regulatory subunits and their potential functions during transformation. The possibility of the existence of an endogenous inhibitor should also be investigated, since an endogenous inhibitor of the closely related phosphatase PP2A, has been identified in cells undergoing blast crisis in chronic myeloid leukaemia [46] .
A key finding in these studies was that PP4c influenced the phosphorylation status of PEA15, especially since PEA15 is itself implicated in the regulation of cell proliferation and apoptosis [27] . Proteomic analysis has shown that changes in PP4 expression levels affect the phosphorylation status of many proteins involved in apoptosis and cell proliferation, including PEA15 [27] . PEA15 is a multi-functional protein that has been implicated in the regulation of major intracellular processes including proliferation and apoptosis, and its function is tightly regulated by its phosphorylation at two serine residues, Ser104 and Ser116 [27] . Both CaMKII and AKT phosphorylate PEA15 at Ser116 [47] [48] [49] and, more recently, AMPK was reported to act as an upstream kinase of PEA15 in both normal and cancerous breast epithelial cells [36] . Phosphatases play an equally important role as kinases in regulating the phosphorylation state of PEA15. In this regard, a loss of PTEN function commonly seen in tumour cells is associated with an increased PEA15 phosphorylation at Ser116 and an inhibition of Fas-mediated apoptosis [50] .
However, evidence suggests that PTEN does not dephosphorylate PEA15 directly, but it modulates its phosphorylation level by controlling AKT activity [50] . In this study, we show that PP4c also regulates the phosphorylation of PEA15 at Ser116.
Over-expression of PP4c (which correlated with increased apoptosis and reduced proliferation), caused a significant decrease in the phosphorylation level of PEA15.
Conversely, down-regulation of PP4c (which stimulated proliferation and inhibited apoptosis) prevented the de-phosphorylation of PEA15, leading to an increase in the content of its phosphorylated form at Ser116. Consistent with these observations, others have reported that the non-phosphorylated form of PEA15 binds to the extracellular signal-regulated kinase 1/2 (ERK1/2), preventing its nuclear accumulation, leading to the inhibition of cell proliferation [30, 31] . On the other hand, phosphorylation of PEA15 on Ser116 promotes its binding to Fas-associated death domain protein (FADD) via its DED domain, preventing FADD-mediated activation of caspases and the formation of the death inducing signalling complex (DISC), leading to the inhibition of the extrinsic apoptotic pathway [30, 33, 47] .
Down-regulation of PEA15 expression was found to inhibit cell growth and to reduce viable cell number and viability, confirming an anti-apoptotic role for PEA15 in breast cancer cells. Crucially, PP4c had no effect on apoptosis in cells with prior knockdown of PEA15 expression, suggesting that the induction of apoptosis by PP4c is mainly mediated through PEA15. Consequently, PP4c may be involved in mediating the switch of PEA15 from a tumour promoter to a tumour suppressor. As discussed above, recent studies have shown that AMPK directly phosphorylates PEA15 at Ser116, thereby converting it to a tumour promoter, resulting in increased survival and anchorage-independent growth of normal and breast cancer cells, both in vivo and in vitro [36] . Thus, PP4c which dephosphorylates PEA15, may counteract the effects of AMPK by switching the activity of PEA15 from a tumour promoter to a tumour suppressor. In this regard, the balance in the activities of AMPK and PP4c are likely to be crucial in determining the phosphorylation status of PEA15 and consequently, the development and progression of breast cancer.
In summary, oncogenic activation of protein kinases is a common feature in breast cancer, and many anticancer drugs that target these enzymes are now available.
Protein phosphorylation is also controlled by protein phosphatases which, compared to kinases, are relatively under-studied. Our studies indicate that PP4c plays a critical role in the delicate balance of cell survival and cell death in breast cancer cells and that these effects are mediated mainly through the dephosphorylation of PEA15, switching the activity of this molecule from a tumour-promoter to a tumoursuppressor. Our study also highlights the high potential therapeutic value of targeting PEA15 and its interactions, which may provide a wider window of opportunities to treat breast cancer. These findings suggest that modulating the levels and activities of PP4c and/or PEA15 may prove important novel strategies for the treatment of breast cancer. 
